Oruka Therapeutics (NASDAQ:ORKA) Earns Outperform Rating from Analysts at Wolfe Research

Wolfe Research started coverage on shares of Oruka Therapeutics (NASDAQ:ORKA) in a report issued on Tuesday morning, MarketBeat.com reports. The firm issued an outperform rating and a $20.00 target price on the stock.

ORKA has been the subject of a number of other reports. Wedbush reaffirmed an “outperform” rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, November 19th. Stifel Nicolaus began coverage on Oruka Therapeutics in a report on Friday, October 11th. They set a “buy” rating and a $49.00 price target for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a report on Friday, December 20th. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Oruka Therapeutics has a consensus rating of “Buy” and an average price target of $39.86.

Oruka Therapeutics Stock Down 8.5 %

Oruka Therapeutics stock opened at $13.08 on Tuesday. The business’s 50-day moving average price is $17.88. The firm has a market cap of $457.80 million, a price-to-earnings ratio of -2.09 and a beta of 0.77. Oruka Therapeutics has a fifty-two week low of $10.95 and a fifty-two week high of $53.88.

Institutional Trading of Oruka Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ORKA. Charles Schwab Investment Management Inc. acquired a new position in shares of Oruka Therapeutics during the 4th quarter worth approximately $303,000. AlphaCentric Advisors LLC acquired a new stake in Oruka Therapeutics during the fourth quarter worth approximately $119,000. China Universal Asset Management Co. Ltd. bought a new position in Oruka Therapeutics during the 4th quarter worth $144,000. Franklin Resources Inc. acquired a new position in Oruka Therapeutics in the 3rd quarter valued at $17,661,000. Finally, Geode Capital Management LLC bought a new stake in shares of Oruka Therapeutics during the 3rd quarter valued at $343,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.